Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule with the chemical formula C14H12FN5OS2 and a molecular weight of approximately 349.41 g/mol[1][3][6]. It is classified as an experimental diarylthioether benzamide derivative[1]. There are no approved medical indications or clinical trials reported for this compound, and its mechanism of action has not been established in the literature or major drug databases. The compound appears in chemical registries such as DrugBank (DB08210), ChemSpider (ID: 395641), PubChem (CID: 449003), and ChEBI (CHEBI:44132)[1][6][7]. No pharmacological activity, therapeutic use, or biological target has been confirmed.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2-amino-4-fluoro-5-[(1-methyl-1H-imidazol-2-yl)sulfanyl]-N-(1,3-thiazol-2-yl)benzamide.